At 5 years after transplant, graft survival and death-censored graft survival did not significantly differ among the 3 groups (graft survival: 96.0% 95.5% 93.3%, p=0.685; death-censored graft survival: 98.3% 97.5% 100%, p=0.732) (Figure 2). At 5 years after transplant, JNK-IN-7 graft survival and death-censored graft survival did not significantly differ among the 3 groups (graft survival: 96.0% 95.5% 93.3%, p=0.685; death-censored graft survival: 98.3% 97.5% 100%, p=0.732). Five-year BPAR-free survival showed no significant differences among the 3 groups (88.6 88.7 88.6%, p=0.842). Group II Spp1 had the highest rate of clinical rejection (p=0.103) and DGF (p=0.174), but the difference was not statistically significant. Conclusions Female LDKT recipients with possible pregnancy-related pre-sensitization who received grafts from offspring or husbands did not show significantly worse clinical outcomes than those who received grafts from JNK-IN-7 unrelated donors. donor-specific antibody (DSA) formation, delayed graft function (DGF), graft survival, and mortality in each group. DGF was defined as the requirement for dialysis in the first week after kidney transplantation. Statistical analysis Continuous data were compared using one-way ANOVA, test, or Mann-Whitney U-test according to the distribution of the variables. Results are presented as meanSD. Categorical data were compared using the chi-squared test. Kaplan-Meier curves and log-rank tests were used to describe and compare the rates of graft survival and biopsy-proven acute rejection (BPAR)-free survival. Cox proportional hazards model analysis was performed to assess the outcomes of graft survival and acute rejection, using hazard ratios (HRs) and 95% confidence intervals (CIs). We selected variables that are known to have an important impact on the outcomes, including age, BMI, HLA, and ABO mismatch and pre-transplant DSA [14]. Adjusted variables with p 0.2 on univariate analyses were included as variables for multivariate analyses. Multiple imputation was used to address JNK-IN-7 missing data. All statistical analyses were performed with the SPSS Statistics for Windows, version 18.0 f (SPSS, Inc., Chicago, IL, USA) with a p value of 0.05 as the criteria for statistical significance. Results Baseline characteristics of donors and recipients Table 1 shows the baseline characteristics of the study population. Recipients in group I were significantly older (p 0.001) and had a higher body mass index (p 0.001) compared with the other groups. The mean duration of hemodialysis before kidney transplantation was significantly longer in group III compared with the other groups (p=0.032). The number of HLA ABDR mismatches (2.40.9 4.41.2 4.51.2, p 0.001) and HLA DR mismatches (0.80.4 1.61.2 JNK-IN-7 1.40.6, p 0.001) were significantly lower in group I compared with the other groups. ABO-incompatible kidney transplant was more frequent in group II compared with the other groups (20.0% 34.0% 17.9%, p=0.005). Table 1 Baseline characteristics. 49.08.6 42.99.0 years, p 0.001) compared with those in the other groups. The hospitalization period was the longest in group II, but the difference was not statistically significant (p=0.072). Patient survival and death-censored graft survival There were 4 (2.3%), 3 (1.9%), and 3 (5.4%) cases of mortality in group I, group II, and group III, respectively (p=0.352). Causes of mortality JNK-IN-7 were pneumonia (n=4), septic shock (n=3; acute cholangitis, small-bowel infarction, urinary tract infection), malignancy (n=1), suicide (n=1), and unknown (n=1). Group I and group II each had 1 case of death-censored graft failure while group III had none (p=0.709). At 5 years after transplant, graft survival and death-censored graft survival did not significantly differ among the 3 groups (graft survival: 96.0% 95.5% 93.3%, p=0.685; death-censored graft survival: 98.3% 97.5% 100%, p=0.732) (Figure 2). Univariate and multivariate Cox proportional hazards modeling showed that the relationship to the donor was not significantly associated with graft survival (Table 2) or death-censored graft survival (Table 3). Open in a separate window Figure 2 Rates of graft survival and death-censored graft survival at 5 years after transplant. (A) Graft survival rates (96.0% 95.5% 93.3%, p=0.685) and (B) death-censored graft survival rates (98.3% 97.5% 100%, p=0.732). Kaplan-Meier curves and log-rank tests were used to describe and compare the rates of graft survival. Table.